When WADA formally banned meldonium on 1 January 2016, laboratories soon reported an extraordinary cluster of positive tests. More than 170 athlete cases emerged in a relatively brief period, involving prominent competitors such as Russian ice dancer Ekaterina Bobrova, Ethiopian-Swedish runner Abeba Aregawi, Ethiopian distance runner Endeshaw Negesse, Russian cyclist Eduard Vorganov, Ukrainian biathletes Olga Abramova and Artem Tyshchenko, UFC fighter Liliya Shakirova, and boxer Alexander Povetkin. Bobrova said she had been careful after learning that meldonium had been added to the prohibited list, yet still tested positive, while many other athletes maintained that they had ceased using it in 2015. WADA later issued guidance allowing less than 1 microgram per milliliter for tests conducted before 1 March 2016, citing preliminary evidence that the substance could take weeks or months to leave the body. Numerous early cases were subsequently dropped or softened when athletes established that their use predated the ban or that residual concentrations were consistent with earlier ingestion. The crisis became a landmark dispute over notice, pharmacological persistence, and the fairness of anti-doping enforcement: WADA classified meldonium as a metabolic modulator, but independent experts and the manufacturer Grindeks noted that strong evidence of performance enhancement was lacking, with anti-doping specialist Don Catlin calling the evidence of athletic benefit effectively nonexistent.
Follow the sources
Status and citations are supplied by the archive. AI concept art is an interpretation, not historical evidence.